NEU 3.32% $20.52 neuren pharmaceuticals limited

Ann: Neuren completes enrolment in Pitt Hopkins Phase 2 trial, page-12

  1. 2,202 Posts.
    lightbulb Created with Sketch. 324
    Jon, has mentioned before, if there were major problems with the PMS trial, management would have STOPPED it.
    One can only speculate that NO problems occurred with the Dosage or tolerability of NNZ 2591, what we Don't know however is the efficacy and that's what we are waiting for.
    Not long to go before that happens.
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.